Drug Trial Radar · NCT03114943
Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age
Last checked: Nov 19, 2026Latest source record: May 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
516
Actual
Start
Jul 14, 2016
Primary completion
Jun 28, 2017
Study completion Jun 28, 2017
Sponsor
- Lead sponsor
- SK Bioscience Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 months, up to 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study assesses non-inferiority by comparing seroconversion rate of NBP608 to Varivax which are indicated for active immunization for prevention of varicella. Total of 488 subjects (244 subjects per treatment arm) of 12 months to 12 years of age are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.
Conditions
- Varicella
Interventions
NBP608Biological
Preparation of the Oka/SK strain of live, attenuated varicella virus
VarivaxBiological
Preparation of the Oka/Merck strain of live, attenuated varicella virus
Primary outcomes
What the sponsor says the trial is designed to measure.
- seroconversion rate by FAMA (Fluorescent Antibody to Membrane Antigen) assayTime frame: 6 weeks after IP(Investigational Product) vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
De La Salle Health Sciences Institute
Dasmariñas, Cavite, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.